In adults with type 2 diabetes and existing heart disease, tirzepatide is associated with a lower rate of procedures to reopen blocked heart arteries compared to dulaglutide, based on a study...
Mechanism
Synthesis from 1 study
Tirzepatide helps the body manage blood sugar and fat better than dulaglutide, which makes the fatty deposits in heart arteries smaller and less likely to burst. When these deposits don’t rupture, blood clots are less likely to form and block arteries, so fewer people need stents or bypass surgery.
Most probable mechanism
Tirzepatide helps the body use sugar and fat better, which lowers harmful fats and inflammation in the blood. This makes the fatty buildups in heart arteries less likely to grow or break open, so fewer blockages form that need stents or bypass surgery.
Tirzepatide enhances glucose-dependent insulin secretion and suppresses glucagon release, leading to lower fasting and postprandial blood glucose levels
Reduced hyperglycemia decreases oxidative stress and endothelial dysfunction in coronary arteries
Tirzepatide promotes weight loss and reduces circulating free fatty acids and triglycerides, lowering lipid accumulation in arterial walls
Reduced lipid burden and inflammation decrease macrophage infiltration and foam cell formation in atherosclerotic plaques
Stabilization of atherosclerotic plaques reduces the incidence of rupture-triggered thrombosis, lowering the need for coronary revascularization procedures
Evidence from Studies
Supporting (1)
Community contributions welcome
Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.